News: Simtuzumab

We provide the latest news and info on Simtuzumab


The Nation
Place your bets: Biotechs hustle along new drugs for blockbuster liver diseases
FierceBiotech
... at the next-gen liver drug developers working in areas like NASH as well as hepatitis B. The trend piece highlights Intercept, expected to head into a pivotal Phase III next year, as werll as Gilead's ($GILD) LOXL2-targeting antibody simtuzumab for ...
After hepatitis C cure, companies target next big liver disease marketKFGO

all 42 news articles »

Published on Tuesday 18th of November 2014 08:59:39 AM Read more...

Takeda enlists GE's aid to tackle liver fibrosis epidemic
PMLiVE
Gilead's simtuzumab is in phase II testing in NASH, while Intercept's obeticholic acid candidate has just cleared a phase II trial and will enter phase III in 2015. France's Genfit has GFT505 in phase IIb trials for NASH while Galectin's GM-MD-02 for ...

and more »

Published on Tuesday 18th of November 2014 08:59:39 AM Read more...

BMS takes option to buy fibrosis firm Galecto
PMLiVE
... in IPF aimed at reducing the chronic cough associated with the disease. Drugs for IPF in phase II trials include AstraZeneca/MedImmune's tralokinumab, Roche's lebrikizumab, Gilead Sciences' simtuzumab, Biogen Idec's STX-100 and FibroGen's FG-3019.

and more »

Published on Tuesday 18th of November 2014 08:59:39 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts